About Fizimed
Fizimed is a company based in Strasbourg (France) founded in 2017 by Emeline Hahn, Julien Guay, Allan Mabilais, and Paul Grandemange. Fizimed has raised $4.35 million across 1 funding round from investors including UNIQA Group, Bpifrance and UI Investissement. Fizimed operates in a competitive market with competitors including Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and Atlantic Therapeutics, among others.
- Headquarter Strasbourg, France
- Founders Emeline Hahn, Julien Guay, Allan Mabilais, Paul Grandemange
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fizimed
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.35 M (USD)
in 1 rounds
-
Latest Funding Round
$4.35 M (USD), Series A
Mar 13, 2025
-
Investors
UNIQA Group
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Fizimed
Fizimed has successfully raised a total of $4.35M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.35 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fizimed
Fizimed has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include UNIQA Group, Bpifrance and UI Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UI Investissement is engaged in private equity and investment services.
|
Locked | Locked | Locked | |
|
Diversified insurance firm
|
Locked | Locked | Locked | |
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Locked | Locked | Locked |
Investor details for Fizimed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fizimed
Investment portfolio details for Fizimed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fizimed
Detailed financials for Fizimed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fizimed Comparisons
Peer comparison for Fizimed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fizimed
Fizimed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and Atlantic Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sacral neuromodulation devices are developed for urinary and bowel control.
|
|
| Locked | Locked | Locked |
Medical products for female lower urinary tract dysfunctions are provided.
|
|
| Locked | Locked | Locked |
Bioelectrical therapies for peripheral nervous system disorders are developed.
|
|
| Locked | Locked | Locked |
Miniaturized injectable neuromodulation devices are developed for chronic diseases.
|
|
| Locked | Locked | Locked |
Non-invasive wearable devices for pelvic floor strengthening are developed.
|
|
| Locked | Locked | Locked |
Developer of active implantable devices for urological incontinence
|
Detailed competitors of Fizimed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fizimed
Complete news archive for Fizimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fizimed
Fizimed was founded in 2017 and raised its 1st funding round 8 years after it was founded.
Fizimed is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.
Emeline Hahn is the current CEO of Fizimed. They have also founded this company.
Fizimed is a funded company, having raised a total of $4.35M across 1 funding round to date.
Fizimed was founded in 2017 in Strasbourg, France, and operates in the medical device sector. The Emy device, a wireless probe linked to a mobile application, is produced for perineal rehabilitation. It supports home-based exercises that supplement practitioner-led sessions, with progress monitored remotely by healthcare providers. Operations focus on enabling independent patient training while integrating with professional care protocols.
Fizimed's top competitors include Axonics, NeuSpera Medical and Laborie Medical.
Fizimed has 3 investors. Key investors include UNIQA Group, Bpifrance, and UI Investissement.